Munich Cancer Registry



- Baseline statistics
- Selection Matrix
- Homepage
- Deutsch

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Survival

C54: Corpus cancer

Year of diagnosis	1988-2012
Patients	9,617
Diseases	9,618
Cases evaluated	5,843
Creation date	03/25/2014
Export date	02/12/2014
Population (females)	2.3 m



http://www.tumorregister-muenchen.de/en/facts/surv/surv_C54_E.pdf




Figure 1a. Relative survival of patients with corpus cancer by period of diagnosis. Included in the evaluation are 5,843 cases diagnosed between 1988 and 2012.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2009, and are represented by green diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1988, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

I	Period	of dia	gnosis		
	1988-1997 1998+				
	n=1,	826	n=4,	017	
Years	obs. %	rel. %	obs. %	rel. %	
0	100.0	100.0	100.0	100.0	
1	91.7	94.2	90.7	92.9	
2	84.6	89.2	84.7	88.7	
3	78.7	85.2	79.8	85.5	
4	74.1	82.4	75.9	83.1	
5	71.5	81.7	73.0	81.8	
6	68.9	80.8	69.6	79.7	
7	65.4	79.0	67.1	78.6	
8	62.7	77.8	64.6	77.5	
9	59.7	76.3	62.0	76.1	
10	57.7	75.8	58.9	74.1	
11	54.8	74.2	57.0	73.1	
12	52.4	73.1	55.3	73.1	
13	50.4	72.4	53.7	72.8	
14	48.3	72.0	51.1	71.5	
15	45.7	70.6			
16	43.5	69.7			
17	40.8	68.1			
18	38.3	66.4			
19	35.2	63.6			
20	32.3	61.0			
	Years 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	1988- n=1, Years obs. % 0 100.0 1 91.7 2 84.6 3 78.7 4 74.1 5 61.8 7 65.4 8 62.7 9 59.7 10 57.7 11 54.8 12 52.4 13 50.4 14 48.3 15 45.7 16 43.5 17 40.8 18 38.3 19 35.2	1988-1997 n=1,826 years obs. % rel. % 0 100.0 100.0 1 91.7 94.2 2 84.6 89.2 3 78.7 85.2 4 74.1 82.4 5 71.5 81.7 6 68.9 80.8 7 65.4 79.0 8 62.7 77.8 9 59.7 76.3 10 57.7 75.8 11 54.8 74.2 12 52.4 73.1 13 50.4 72.4 14 48.3 72.0 15 45.7 70.6 16 43.5 69.7 17 40.8 68.1 18 38.3 66.4 19 35.2 63.6	n=1,826 n=4, obs.% Years obs.% rel.% obs.% 0 100.0 100.0 100.0 1 91.7 94.2 90.7 2 84.6 89.2 84.7 3 78.7 85.2 79.8 4 74.1 82.4 75.9 5 71.5 81.7 73.0 6 68.9 80.8 69.6 7 65.4 79.0 67.1 6 89.7 77.8 64.6 9 59.7 76.3 62.0 10 57.7 75.8 58.9 11 54.8 74.2 57.0 12 52.4 73.1 55.3 13 50.4 72.4 53.7 14 48.3 72.0 51.1 15 45.7 70.6 10 14 48.3 72.0 51.1 15 45.7 70.6	

Table 1b. Observed (obs.) and relative (rel.) survival of patients with corpus cancer by period of diagnosis for period 1988-2012 (N=5,843).




Figure 2a. Observed, expected and relative survival of the total cohort with corpus cancer. Included in the evaluation are 5,843 cases diagnosed between 1988 and 2012.

	Group	
	Total	cohort
	n=5,	
Years	obs. %	
0	100.0	100.0
1	91.0	93.3
2	84.6	88.9
3	79.4	85.3
4	75.2	82.8
5	72.4	81.7
6	69.4	80.2
7	66.4	78.7
8	63.7	77.5
9	60.9	76.0
10	58.5	75.1
11	55.8	73.7
12	53.6	72.9
13	51.6	72.3
14	49.4	71.6
15	46.9	70.4
16	44.7	69.6
17	42.0	67.9
18	39.4	66.2
19	36.1	63.4
20	33.2	60.8

Table 2b. Observed (obs.) and relative (rel.) survival of the total cohort with corpus cancer for period 1988-2012 (N=5,843).




Figure 3a. Relative survival of patients with corpus cancer by age category. Included in the evaluation are 5,843 cases diagnosed between 1988 and 2012.




Figure 3b. Observed survival of patients with corpus cancer by age category. Included in the evaluation are 5,843 cases diagnosed between 1988 and 2012.

Age category												
	0-59	yrs	2	2	60-69	9 yrs	70-79 yrs					
	n=1,424		n=1,897		n=1,	683	n=839					
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %				
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0				
1	95.0	95.3	94.6	95.5	89.8	92.1	78.6	86.7				
2	92.3	92.9	89.3	91.0	82.8	87.5	64.5	78.5				
3	89.5	90.5	85.3	87.8	76.7	83.8	53.9	72.8				
4	87.8	89.2	82.7	86.1	70.6	80.0	45.4	69.0				
5	86.9	88.6	80.5	85.0	67.1	78.8	39.7	68.6				
6	84.5	86.6	79.2	84.7	63.3	77.8	33.4	65.4				
7	83.5	86.1	76.9	83.7	59.1	76.3	27.1	61.7				
8	82.5	85.5	75.2	83.2	54.8	75.0	22.9	59.6				
9	80.9	84.5	73.1	82.4	50.4	73.4	18.9	59.6				
10	80.0	84.0	70.9	81.9	46.9	72.3	15.9	59.2				
11	78.6	83.2	69.9	81.9	41.4	69.4	12.7	59.2				
12	77.8	82.9	67.7	81.9	37.7	68.7						
13	76.8	82.4	65.9	81.9	35.0	67.7						
14	75.5	81.9	63.8	81.9	31.6	67.7						
15	74.9	81.6	61.1	81.8	27.1	67.2						
16	74.9	81.6	58.1	81.8	23.9	66.5						
17	72.8	81.6	54.6	80.6	20.8	66.1						
18	71.8	81.4	50.3	78.1	18.4	66.1						
19	67.2	77.9	46.0	75.8	16.1	66.1						
20	67.2	77.9	42.3	74.8								

Table 3c. Observed (obs.) and relative (rel.) survival of patients with corpus cancer by age category for period 1988-2012 (N=5,843).




Figure 4a. Relative survival of patients with corpus cancer by FIGO. For 3,594 of 3,752 cases diagnosed between 1998 and 2010 valid data could be obtained for this item. For a total of 3,456 cases an evaluable classification was established. The grey line represents the subgroup of 296 patients with missing values regarding FIGO (7.9% of 3,752 patients, the percent values of all other categories are related to n=3,456).

Due to substantial changes in stage classification schemes long-term survival statistics over decades could not be created.

	FIGO													
	1/	4	I	3	IC	2	IIA		IIB		IIIA		IIIB	
	n=4	182	n=1,	472	n=7	733	n=94		n=2	225	n=2	213	n=53	
Years	obs. %	rel. %												
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	97.3	98.7	98.0	99.6	94.6	97.4	91.4	93.7	90.8	92.8	76.8	79.1	64.3	65.0
2	95.2	98.2	95.5	98.8	88.1	93.4	83.0	87.1	82.3	85.8	60.6	64.0	36.4	37.8
3	91.8	96.3	92.5	97.8	83.2	90.9	80.4	85.6	76.7	81.7	50.1	54.4		
4	90.1	96.1	89.6	96.5	79.4	89.3	72.4	79.7	71.3	77.9	45.3	50.2		
5	88.4	95.9	87.2	95.6	74.7	87.1	66.7	74.8	68.5	76.2	42.0	46.9		
6	84.9	94.0	84.6	94.7	70.4	84.3	57.7	66.4	64.1	72.9	40.3	45.4		
7	82.5	92.4	82.6	94.1	67.1	83.3	54.8	63.3	59.5	68.8	37.9	44.3		
8	80.7	92.4	81.1	94.1	62.2	79.6			54.0	64.4	34.5	40.9		
9	77.8	90.8	79.5	94.1	56.1	74.2			50.7	62.2	34.5	40.1		
10	76.9	90.6	75.7	93.1	50.7	69.1			50.7	61.5	34.5	39.2		

FIGO											
cont'd	IV	Ά	IV	'B	NA/N	NOS					
	n=	24	n=1	160	n=2	296					
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %					
0	100.0	100.0	100.0	100.0	100.0	100.0					
1			45.2	46.2	77.0	80.2					
2			31.0	31.8	65.6	70.8					
3			20.7	21.8	55.4	61.5					
4					47.4	54.1					
5					45.6	52.6					
6					41.6	48.9					
7					38.7	46.4					
8					38.1	46.2					
9					35.2	43.9					
10					30.6	39.2					

Table 4b. Observed (obs.) and relative (rel.) survival of patients with corpus cancer by FIGO for period 1998-2010 (N=3,456).




Figure 4c. Relative survival of patients with corpus cancer by extent of disease. For 5,561 of 5,843 cases diagnosed between 1988 and 2012 valid data could be obtained for this item. For a total of 2,562 cases an evaluable classification was established. The grey line represents the subgroup of 3,281 patients with missing values regarding extent of disease (56.2% of 5,843 patients, the percent values of all other categories are related to n=2,562).

	Extent of disease											
		Loo	cal	Regi	Regional		tant	NA/N	NA/NOS			
		n=2,	113	n=2	214	n=235		5 n=3,281				
Year	ſS	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %			
0		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0			
1		95.4	97.4	82.7	83.8	45.5	46.5	92.0	94.6			
2		91.0	94.7	63.7	65.7	31.4	32.4	85.6	90.4			
3		86.8	92.1	52.2	54.4	20.8	22.0	80.4	87.3			
4		82.9	89.8	45.3	48.6	15.7	17.2	76.1	84.8			
5		81.0	89.3	40.8	44.5	15.7	16.7	72.9	83.4			
6		78.0	88.1	40.0	43.4	14.8	16.2	69.6	81.8			
7		75.1	86.7	38.1	42.4			66.3	80.1			
8		72.4	85.7	37.1	41.4			63.4	78.6			
9		70.3	85.2	35.9	41.3			59.8	76.5			
10		67.8	84.3	35.9	41.3			57.3	75.4			

Table 4d. Observed (obs.) and relative (rel.) survival of patients with corpus cancer by extent of disease for period 1988-2012 (N=2,562).




Figure 4e. Conditional relative 5-year survival of patients with corpus cancer by extent of disease. For 5,561 of 5,843 cases diagnosed between 1988 and 2012 valid data could be obtained for this item. For a total of 2,562 cases an evaluable classification was established. The grey line represents the subgroup of 3,281 patients with missing values regarding extent of disease (56.2% of 5,843 patients, the percent values of all other categories are related to n=2,562).

	Extent of disease													
	Loc	al	Regio	onal	Dist	Distant		IOS						
		Cond. surv. %		Cond. surv. %				Cond. surv. %		Cond. surv. %				
Years	n	5 yrs	n	5 yrs	n	5 yrs	n	5 yrs						
0	2,113	89.6	214	44.5	235	16.7	3,281	83.4						
1	1,901	90.8	165	51.6	97	34.9	2,897	86.8						
2	1,641	92.2	112	64.4			2,532	89.3						
3	1,436	93.8	80	75.4			2,205	91.5						
4	1,235	96.0	64	85.2			1,923	91.7						
5	1,068	95.4	52	93.3			1,673	92.5						
6	904	96.5	46	92.6			1,470	92.2						
7	814	97.6	38	94.1			1,276	93.1						
8	720	98.8	32	94.7			1,098	94.4						
9	641	98.3	29	95.9			933	96.9						
10	551	97.3					819	97.5						

Table 4f. Conditional relative 5-year survival of patients with corpus cancer by extent of disease for period 1988-2012 (N=2,562).

Conditional relative survival rates refer to the relative survival probability, in this case for 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100%) under the condition of being alive for a certain time period (x-axis in Figure 4c). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup extent of disease="Local", who are alive at least 3 years after cancer diagnosis, the conditional relative 5-year survival rate is 93.8% (n=1,436).




Figure 5a. Observed post-progression survival of 938 patients with corpus cancer diagnosed between 1988 and 2012 (incl. M1). These 938 patients with documented progression events during their course of disease represent 16.1% of the totally 5,843 evaluated cases. Patients with cancer relapse documented via death certificates only were excluded (n=290, 5.0%). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously. The

NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "All types" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

		Type of	f progressior	า	
	All types	Local relapse	Lymph node recurrence	Distant metastasis	NOS
	n=938	n=351	n=86	n=658	n=105
Months	%	%	%	%	%
0	100.0	100.0	100.0	100.0	100.0
12	50.2	57.7	49.2	40.9	45.5
24	34.7	44.6	31.6	27.3	23.7
36	25.8	36.9		18.7	
48	21.0	30.3		14.8	
60	18.7	27.7		13.2	

Table 5b. Observed post-progression survival of patients with corpus cancer for period 1988-2012 (N=938).



Shortcuts

AS Assembled survival chart (observed, expected, relative) CS Conditional survival DCO Death certificate only. The death certificate provides the only notification to the registry. Munich Cancer Registry, Germany (Tumorregister München) MCR NA Not available NCI National Cancer Institute, USA NOS Not otherwise specified Observed/overall survival (Kaplan-Meier estimate) OS PPS Post-progression survival RS Relative Survival. Ratio of observed and expected survival (derived from the normal population) SEER Surveillance, Epidemiology, and End Results, USA TTP Time to progression Date of entry: Date of diagnosis Event (Progression): First local recurrence, lymph node relapse or distant metastasis, unspecified recurrence First all-cause recurrence is illustrated by survival curves (Kaplan-Meier estimate). First local recurrence, lymph node relapse or distant metastasis are depicted cumulatively, where applicable ("reverse" Kaplan-Meier estimate). UICC Union for International Cancer Control, Geneva

Recommended Citation

Munich Cancer Registry. Survival C54: Corpus cancer [Internet]. 2014 [updated 2014 Mar 25; cited 2014 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/surv_C54_E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Munich Cancer Registry

Index of figures and tables

Fig./Tb	l.	Page
1a	Relative survival by period of diagnosis (chart)	2
1b	Survival by period of diagnosis (table)	3
2a	Survival of total cohort (chart)	3
2b	Survival of total cohort (table)	4
3a	Relative survival by age category (chart)	4
3b	Observed survival by age category (chart)	5
3c	Survival by age category (table)	5
4a	Relative survival by FIGO (chart)	6
4b	Survival by FIGO (table)	6
4c	Relative survival by extent of disease (chart)	7
4d	Survival by extent of disease (table)	8
4e	Conditional survival by extent of disease (chart)	8
4f	Conditional survival by extent of disease (table)	9
5a	Observed post-progression survival (chart)	9
5b	Observed post-progression survival (table)	10